Biomarin presents new data on the effect of long-term treatment with Voxzogo® (vosoritide) on arm span, bone health and growth in children with achondroplasia

robot
Abstract generation in progress

BioMarin Pharmaceutical Inc. has released new data regarding the long-term impact of its drug, Voxzogo (vosoritide), on children suffering from achondroplasia. The study focuses on how the treatment affects arm span, overall bone health, and growth development in these children. More detailed information requires registration on the MarketScreener website.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin